Boston Scientific (NYSE:BSX) has enrolled the first patients in the global FARADIGM trial. The study evaluates the Faraflex pulsed field ablation device for the treatment of atrial fibrillation. This ...
Original Image Link
Source:finance.yahoo.com
Original Image Link
Source:finance.yahoo.com
Posted: 2026-07-23 05:30:00
















